Eurobio Scientific SA
PAR:ALERS

Watchlist Manager
Eurobio Scientific SA Logo
Eurobio Scientific SA
PAR:ALERS
Watchlist
Price: 25.45 EUR 0.2% Market Closed
Market Cap: 254.6m EUR
Have any thoughts about
Eurobio Scientific SA?
Write Note

Net Margin
Eurobio Scientific SA

4.6%
Current
18%
Average
-7.8%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
4.6%
=
Net Income
6.6m
/
Revenue
144.1m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
FR
Eurobio Scientific SA
PAR:ALERS
255.2m EUR
5%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
340.8B USD
9%
US
Amgen Inc
NASDAQ:AMGN
156.4B USD
12%
US
Gilead Sciences Inc
NASDAQ:GILD
129.7B USD
2%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.9B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
124.5B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.8B USD
31%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36.3B EUR
-5%
No Stocks Found

Eurobio Scientific SA
Glance View

Market Cap
255.2m EUR
Industry
Biotechnology

Eurobio-Scientific SA engages in designing, development and commercialization of tests diagnosis in the fields of transplantation, infectious diseases, autoimmunity and oncology, as well as products for research in the field of life sciences. The company is headquartered in Les Ulis, Ile-De-France. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.

ALERS Intrinsic Value
16.62 EUR
Overvaluation 35%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
4.6%
=
Net Income
6.6m
/
Revenue
144.1m
What is the Net Margin of Eurobio Scientific SA?

Based on Eurobio Scientific SA's most recent financial statements, the company has Net Margin of 4.6%.

Back to Top